GlassScriptPhysician profile
Deborah Riney
NPI 1386653764
$6,636.85
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,650 · 2022: $2,914 · 2023: $2,056 · 2024: $17.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,073.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $920.03 | 2021-2023 | |
| Abbvie INC. | $880.27 | 2021-2023 | |
| Alkermes, INC. | $788.32 | 2021-2023 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $719.03 | 2021-2023 | Ingrezza |
| Lundbeck LLC | $392.40 | 2021-2023 | Brintellix, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $383.25 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $373.72 | 2021-2023 | Rexulti, Abilify Maintena, Nuedexta |
| Neuronetics, INC. | $273.42 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.91 | 2021-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $185.46 | 2022-2023 | Belsomra |
| Neos Therapeutics, LP | $163.93 | 2021-2023 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $152.78 | 2021-2022 | |
| Bausch Health US, LLC | $139.50 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $139.13 | 2022-2023 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $127.26 | 2021-2023 | Hetlioz, Fanapt |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $97.50 | 2022-2023 | Qelbree |
| Noven Pharmaceuticals, INC. | $96.19 | 2023 | Xelstrym |
| Noven Therapeutics, LLC | $77.66 | 2023 | Secuado |
| Tris Pharma INC | $74.36 | 2022-2023 | Dyanavel Xr |
| Eisai INC. | $70.50 | 2021 | |
| Axsome Therapeutics, INC. | $62.39 | 2022-2023 | Auvelity |
| Ironshore Pharmaceuticals INC. | $61.67 | 2022 | |
| Alfasigma USA, INC. | $47.64 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $47.37 | 2022 | |
| Corium, LLC | $46.53 | 2022-2023 | Azstarys |
| Jazz Pharmaceuticals INC. | $35.06 | 2022 | |
| Idorsia Pharmaceuticals US INC | $30.39 | 2023 | Quviviq |
| Almatica Pharma LLC | $20.97 | 2023 | Loreev Xr |
| Orexo US, INC. | $20.22 | 2021 | |
| Owp Pharmaceuticals, INC. | $14.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Riney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.